A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
AstraZeneca
Seagen Inc.
Tango Therapeutics, Inc.
Novartis
Merck Sharp & Dohme LLC
TCR2 Therapeutics
TCR2 Therapeutics
Toray Industries, Inc
Eli Lilly and Company
Lisata Therapeutics, Inc.
Compass Therapeutics
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc